Adverse reactions of the new generation of tumor immunotherapy and its management strategy

In recent years, tumor immunotherapy has attracted more attention because of its remarkable curative effect in patients with advanced cancer, but often accompanied by immune related adverse events. Understanding the immune related adverse reaction rate, possible mechanism and adverse reaction evaluation criteria and treatment principle of the immune checkpoint inhibitors such as Ipilimumab, Nivolumab and Pembrolizumab, has important significance for the treatment of malignant tumor. Key words: Immunotherapy; Drug toxicity